Shots:

• The P-III TIDES study involves assessing two doses of TAK-003 (0.5mL- SC on day 1 & 90) vs PBO to prevent laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 20-000+ children and adolescents
• Results: @36mos. after the second dose- 62.0% VE against VCD; 65.0% VE in seropositive; 54.3% VE in seronegative individuals. TAK-003 also demonstrated 83.6% VE against hospitalized dengue- with 86.0% VE in seropositive & 77.1% VE in seronegative individuals
• The regulatory filing in the EU and dengue-endemic countries is under progress while the company plan to regulatory application in the US in late 2021

  Ref: Takeda | Image: Takeda